Core Viewpoint - ST Pava is currently facing legal issues involving its former chairman and general manager, Zhang Bao, who is under investigation for embezzlement and misappropriation of funds, but the company asserts that its operations remain normal and unaffected by these events [1][3]. Group 1: Legal Issues - On February 6, ST Pava received a notice from the People's Procuratorate of Zhuji City regarding the prosecution of Zhang Bao for embezzlement and misappropriation of funds [1]. - Zhang Bao was officially arrested on September 7, 2025, for the crime of embezzlement [3]. - Prior to his arrest, Zhang Bao submitted his resignation due to health reasons on May 22, 2025, and continued to hold other positions within the company [3]. Group 2: Financial Performance - As of the end of September 2025, Zhang Bao held 16.56 million shares of ST Pava, representing a 10.41% stake, making him the second-largest shareholder [4]. - ST Pava's 2025 annual profit forecast indicates a net loss of between 550 million to 700 million yuan, which is an improvement compared to the previous year, reducing losses by 26.5 million to 177 million yuan [5]. - The company has accumulated losses exceeding 1.5 billion yuan over the past three years, primarily due to high fixed costs and impairment provisions on various assets [5]. Group 3: Company Operations - ST Pava is engaged in the research, development, production, and sales of pharmaceutical products and related health services [5]. - The company has been placed under special risk warning due to a negative audit opinion on its internal controls for the 2024 financial report [5]. - As of February 6, 2025, ST Pava's stock price decreased by 0.10%, closing at 10.46 yuan, with a total market capitalization of 1.66 billion yuan [5].